Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment

Antibody-Drug Conjugates (ADCs) are basically a targeted drug delivery system where tumour antigenspecific antibodies are used for targeting particular tumor cells and cytotoxic materials are conjugated with it by a linker molecule. Till now, twelve ADCs have been approved by FDA for clinical use. Majority of the approved ADCs are against hematological cancer. Here in this review, we will discuss the combinations of targeted ligands (antigen) specific antibodies, different types of cytotoxic drugs (payload/warheads) and linker moieties which are being used for the development of successful FDA approved ADCs. We will discuss new ADC formulations which completed clinical trials or underwent advance phases of clinical trials against different types of solid tumours. New ADC formulation or recently developed its prototypes against solid tumour models in preclinical studies will be discussed precisely in this review article.